UAE Approves VIVUS’ QSYMIA® for Obesity Treatment

VIVUS LLC, a leading biopharmaceutical company, has announced the approval of QSYMIA® (phentermine and topiramate extended-release capsules) CIV in the United Arab Emirates (UAE) for the treatment of obesity in adults and children aged 12 and older. The UAE is the first country in the Middle East to authorize QSYMIA, marking a major step in addressing the growing obesity epidemic. VIVUS, in partnership with PharmaAccess and distributor Alphamed Drug Store, aims to enhance patient access to effective weight management therapies in alignment with the UAE’s vision for public health improvement.

John Amos, CEO of VIVUS, emphasized the company’s commitment to fighting obesity globally, stating, “With QSYMIA’s availability in the UAE, we are not only expanding access but also reinforcing our mission to improve patient care worldwide.” The approval comes as the World Obesity Federation projects that by 2035, over 7.5 million people in the UAE could be living with obesity. As part of its global expansion strategy, VIVUS also plans to introduce QSYMIA under the trade name QSIVA® in various European markets, with a goal of reaching over one billion individuals worldwide by the end of 2025.